

Iowa Medicaid Drug Utilization Review (DUR) Commission

August 5, 2026

Meeting Format: Hybrid

Time: 9:30 a.m. – 1:30 p.m.

Location: Lucas State Office Building
Ground Floor, Assembly Room LG20-B
321 E 12th Street
Des Moines, IA 50319

Teams Meeting: <https://teams.microsoft.com/meet/21778015416793?p=5DOGFoQQTT1LCIGUes>

Meeting ID: ID: 217 780 154 167 93

Passcode: Dn9Pd3tQ

Tentative Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of May 6, 2026 Meeting Minutes
 - b) May 2026 DUR Recommendation Letter to HHS
 - c) April 2026 P&T Recommendation Letter
 - d) Annual Chair and Vice Chair Elections
 - e) Annual Conflict of Disclosure
 - f) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
 - a) Fee-for-Service
 - b) Iowa Total Care
 - c) Molina Healthcare
 - d) Wellpoint Iowa
 - e) Comparative Summary
5. Public Comment* (Complete [Speaker Conflict of Interest Disclosure Form](#))
 - Verbal - Must **pre-register** to provide verbal public comment and submit a **completed** conflict of interest disclosure. Must indicate if will be in-person or virtual testimony. Five (5) minute maximum limit.
 - Written – Must submit written comments and a completed conflict of interest disclosure.
 - **All submissions must be received no later than 4:30 p.m. CT July 29, 2026.**
 - **Send to pba_iadur@optum.com. Indicate if providing written or verbal comment.**
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Extended-Release ADHD Stimulants in Children Younger than 6 Years
 - ii. CGRP Antagonist Therapeutic Duplication
 - b) Proposal(s)
 - i. Adherence to Disease Modifying Therapy for Multiple Sclerosis
 - ii. Thiazide Diuretic Use in Members with Gout

- c) Commission Recommendations for Retrospective DUR Agenda Topics
- 7. Prospective DUR
 - a) Chewable Lamotrigine Quantity Limit
- 8. Break (10 minutes)
- 9. Prior Authorization
 - a) Antiemetic-5HT3 Receptor Antagonists/Substance P Neurokinin Products
 - b) Cardiac Myosin Inhibitors
 - c) Incretin Mimetics for Non-Diabetes Indications
 - d) Setmelanotide (Imcivree)
 - e) Topical Acne and Rosacea Products – Topical Clindamycin Review
- 10. Miscellaneous
 - a) DUR Digest Vol. 38, No. 2 – Second Review
- 11. MedWatch
 - [FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia](#)
 - [FDA approves first oral carbapenem therapy for complicated urinary tract infections](#)
 - [FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia](#)
- 12. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay in your comments being considered until the next scheduled meeting. Reference complete public comment policy [here](#).

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
November 4, 2026
Meeting Format: Virtual